Ocular Therapeutix, Inc.

A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers thera...

Ocular Therapeutix announced its participation in multiple scientific conferences in July 2026, including the OIS Retina Innovation Summit and ASRS 44th Annual Meeting in Montreal. The company will present Phase 3 SOL-1 trial results for AXPAXLI (OTX-TKI), its investigational intravitreal axitinib hydrogel for neovascular age-related macular dege...

The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Thera...

Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1.5 million shares for approximately $14.34 million in Q1 2026. The exit comes as Ocular faces investor skepticism following lighter-than-expected Q1 revenue of $10.8 million and widened net losses of $88.6 million, despite positive Phase 3 clinical data for its ...

Ocular Therapeutix announced an Investor Day scheduled for June 17, 2026, in New York City with virtual access. The company also reported additional positive Week 52 data from its landmark SOL-1 Phase 3 trial of AXPAXLI in wet AMD, demonstrating robust disease control with sustained durability and a median time of 39 weeks for CSFT control.